# US 2021/0277420 A1 · Nucleic acid origami structure encapsulated by capsid units > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0277420 A1 - Document ID: US20210277420A1 - Status: Published application - Kind: A1 - Application number: 17/049,059 - Filed: 2019-03-05 - Published: 2021-09-09 - Earliest claimed: 2018-04-23 - Assignees: Geza Ad Ltd. - Applicants: Geza Ad Ltd. - Inventors: Idit KOPATZ - Web page: https://patentgrep.com/patent/US20210277420A1 ## CPC - C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation - C07K 14/005: from viruses - C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34) - C12N 2710/22022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2710/22023: Virus like particles [VLP] - C12N 2710/22042: virus or viral particle as vehicle, e.g. encapsulating small organic molecule - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Provided are particles of nucleic acid origami structure encapsulated by at least twelve capsid units, compositions comprising the same and uses thereof for delivery of nucleic acids to target cells. ## Claims ### Claim at position 1 1-20. (canceled) ### Claim 21 A particle comprising a core and a shell, said core comprising at least one nucleic acid origami structure encapsulated by the shell, said shell comprising at least 12 capsid units, the capsid units comprising one or more capsid proteins wherein the particle has quasi-spherical geometry. ### Claim 22 (depends on 21) The particle of claim 21, wherein the particle has icosahedral geometry. ### Claim 23 (depends on 21) The particle according to claim 21, wherein the diameter of said particle is between 10 and 200 nanometers (nm). ### Claim 24 (depends on 21) The particle according to claim 21, wherein the capsid unit comprises at least five capsid proteins. ### Claim 25 (depends on 21) The particle according to claim 21, wherein each of the capsid units comprises pentamers and/or hexamers of capsid proteins. ### Claim 26 (depends on 21) The particle according to any one of claims 21, wherein the capsid protein is of artificial source or from a natural source. ### Claim 27 (depends on 21) The particle according to claim 21, wherein the capsid protein is a viral protein or a modified viral protein. ### Claim 28 (depends on 27) The particle of claim 27, wherein the viral protein is from a virus of the virus family Polyomaviridae. ### Claim 29 (depends on 27) The particle of claim 27, wherein the viral protein is from a virus selected from the group consisting of: SV40 virus, and human polyomaviruses. ### Claim 30 (depends on 29) The particle of claim 29, wherein the human polyomaviruses are selected from JC virus and BK virus. ### Claim 31 (depends on 21) The particle according to claim 21, wherein the capsid protein is a SV40 virus capsid protein. ### Claim 32 (depends on 21) The particle according to claim 21, wherein the capsid protein is selected from: capsid protein VP1, capsid protein VP2, capsid protein VP3, modified forms thereof, and a combination thereof. ### Claim 33 (depends on 32) The particle according to claim 32, wherein the capsid protein is VP1, or modified forms thereof. ### Claim 34 (depends on 21) The particle according to claim 21, wherein said origami structure is encapsulated by at least 72 capsid units. ### Claim 35 (depends on 21) The particle according to claim 21, wherein said capsid unit comprise a combination of viral protein molecules, or modified forms thereof, selected from the group consisting of: 5 VP1 molecules, 5 VP1 molecules and one VP2 molecule, 5 VP1 molecules and one VP3 molecule, and 5 VP1 molecules and one VP2 molecule or one VP3 molecule. ### Claim 36 (depends on 21) The particle according to claim 21, wherein the origami structure is selected from: single stranded DNA, double stranded DNA, single stranded RNA, double stranded RNA, modified nucleic acids, synthetic nucleic acids, or combinations thereof. ### Claim 37 (depends on 21) A method for delivering a nucleic acid molecule into a target cell comprising infecting the cells with the particles of claim 21. ### Claim 38 (depends on 37) The particle of claim 37, wherein the target cell is selected from an in vitro cell, or a cell harbored in a tissue or an organism. ### Claim 39 (depends on 21) A composition comprising a plurality of the particles of claim 21.